737820-87-0

Upstream product

• 99-27-4 dimethyl 5-aminoisophthalate 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1239340-08-9 C₄₄H₆₅N₅O₁₂ 
• 1239340-09-0 C₃₆H₅₉N₅O₁₀ 
• 1239340-12-5 C₂₀H₂₇N₅O₁₀ 
• 1239340-10-3 C₃₈H₆₀BrN₅O₁₁ 
• 1239340-13-6 [4-((3,5-bis[2-(bis(carboxymethyl)amino)ethylcarbamoyl]phenylcarbamoyl)methyl)-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetic acid 
• 1239340-11-4 C₆₄H₁₀₉N₉O₁₇ 
• 1239340-07-8 benzyl 3,5-bis(2-aminoethylcarbamoyl)phenylcarbamate 
• 887969-66-6 C₁₉H₁₉NO₆ 

Relevant academic research and scientific papers

Synthesis and characterization of dinuclear heterometallic lanthanide complexes exhibiting MRI and luminescence response

A molecule bearing a macrocyclic DOTA-type chelator and an acyclic chelator based on the 5-aminoisophthalamide diethylenediaminetetraacid (5A-PADDTA) was synthesized by linking these two moieties via an amide bond. The ligand has the possibility to complex two identical or different lanthanide ions, depending on the desire for its potential application. Luminescence studies involving titrations of the Eu3+ or Gd3+ complex with Tb 3+ confirm the formation of heterometallic complexes, as well as the presence of different species in the solution. Comparative 1H NMR spectra of the ligand, its Eu3+ complex, and that containing both Eu3+ and Tb3+ proves the existence of respective monometallic or bimetallic species. NMR diffusion measurements on 5A-PADDTA as a model compound indicate the formation of aggregates upon the addition of Y 3+ (chosen as a diamagnetic analogue of lanthanide ions). Hydration values were calculated from the respective luminescence lifetime values. They show the dominance of a q = 1 species for both ions in monometallic complexes, or q = 1 and q = 2 species of ions in aggregated complexes, for DOTA and 5A-PADDTA chelators, respectively.

MACROCYCLIC TERTIARY AMINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention is directed to macrocyclic tertiary amine compounds represented by general formula (I), which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.